The National Health Research Institutes (NHRI) has developed a combination chemotherapy regimen to treat pancreatic cancer that reduces the side effects and extends survival to nearly a year, it said yesterday.
An institute research team’s phase 1 and 2 clinical trials on a chemotherapy regimen of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) showed promising efficacy and safety in treating patients with metastatic pancreatic ductal adenocarcinoma (PDAC), National Institute of Cancer Research associate investigator Chiang Nai-jung (姜乃榕) said.
PDAC is a highly fatal disease, and as pancreatic cancers often do not show symptoms early in their onset, they are often only detected after they have grown large or spread outside the pancreas, meaning that 80 to 85 percent of patients are in the advanced stages of the disease at their time of diagnosis, Chiang said.
Photo: Lin Hui-chin, Taipei Times
The overall five-year survival rate of PDAC is lower than 5 percent, and systemic chemotherapy is the standard treatment for patients with unresectable advanced or metastatic pancreatic cancer, she said.
The median overall survival of patients with metastatic pancreatic cancer who received first-line gemcitabine monotherapy is three to six months, but newer combination chemotherapy regimens — such as folinic acid (also known as leucovorin), fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), and nab-paclitaxel plus gemcitabine (AG) — extended the median overall survival to about eight-and-a-half to 11 months, Chiang said.
Although FOLFIRINOX and AG are more effective than monotherapy, they are associated with a higher degree of hematological toxicity and neutropenia, especially in Asians, she said, adding that their team tried to find other regimens better suited for Asian patients.
Some patients are less willing to tolerate the side effects of chemotherapy, but reducing the chemotherapy dosage might also reduce its efficacy, so the institute has been pursuing better solutions for several years, National Institute of Cancer Research deputy director Liu Ko-jiunn (劉柯俊) said.
The researchers spent four years coming up with the SLOG regimen — a fixed-rate infusion (10mg/m2 per minute) of 800mg/m2 of gemcitabine, followed by 85mg/m2 of oxaliplatin once per two weeks, and an oral dosage of S-1 and 20mg/m2 of leucovorin twice per day in the first seven days of a two-week cycle, Chiang said, adding that it can be used as a first-line treatment for PDAC.
With assistance from the Taiwan Cooperative Oncology Group, National Cheng Kung University Hospital, National Taiwan University Hospital, Linkou Chang Gung Memorial Hospital and Kaohsiung Medical University Chung-Ho Memorial Hospital, a total of 73 patients participated in the two phases of clinical trials.
Researchers found that the median overall survival of patients on the SLOG regimen was 11.4 months, the tumor shrinkage rate was above 30 percent, and the gastrointestinal side effects and rates of neutropenia were also reduced, Chiang said.
The biweekly treatment is a feasible regimen with promising effects and safety for patients with advanced PDAC, and it has been included in the clinical practice guidelines in several hospitals, she said.
The researchers are conducting a randomized phase 2 clinical trial comparing SLOG with a modified FOLFIRINOX regimen in patients with advanced pancreatic cancer, Chiang said.
The team’s research was published in the European Journal of Cancer last month.
Eight Chinese naval vessels and 24 military aircraft were detected crossing the median line of the Taiwan Strait between 6am yesterday and 6am today, the Ministry of National Defense said this morning. The aircraft entered Taiwan’s northern, central, southwestern and eastern air defense identification zones, the ministry said. The armed forces responded with mission aircraft, naval vessels and shore-based missile systems to closely monitor the situation, it added. Eight naval vessels, one official ship and 36 aircraft sorties were spotted in total, the ministry said.
The Ministry of Foreign Affairs (MOFA) today said that if South Korea does not reply appropriately to its request to correct Taiwan’s name on its e-Arrival card system before March 31, it would take corresponding measures to alter how South Korea is labeled on the online Taiwan Arrival Card system. South Korea’s e-Arrival card system lists Taiwan as “China (Taiwan)” in the “point of departure” and “next destination” fields. The ministry said that it changed the nationality for South Koreans on Taiwan’s Alien Resident Certificates from “Korea” to “South Korea” on March 1, in a gesture of goodwill and based on the
Taiwanese officials were shown the first of 66 F-16V fighter jets purchased by Taiwan from the United States, the Ministry of National Defense said yesterday, adding the aircraft has completed an initial flight test and is expected to be delivered later this year. A delegation led by Deputy Minister of National Defense Hsu Szu-chien (徐斯儉) visited Lockheed Martin’s F-16 C/D Block 70 (also known as F-16V) assembly line in South Carolina on March 16 to view the aircraft. The jet will undergo a final acceptance flight in the US before being delivered to Taiwan, the
The New Taipei Metro's Sanyin Line and the eastern extension of the Taipei Metro's Tamsui-Xinyi Line (Red Line) are scheduled to begin operations in June, the National Development Council said today. The Red Line, which terminates at Xiangshan Station, would be connected by the 1.4km extension to a new eastern terminal, Guangci/Fengtian Temple Station, while the Sanyin Line would link New Taipei City's Tucheng and Yingge stations via Sanxia District (三峽). The council gave the updates at a council meeting reviewing progress on public construction projects for this year. Taiwan's annual public infrastructure budget would remain at NT$800 billion (US$25.08 billion), with NT$97.3
RSS